Clinical Trial Update: Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates for Gallium-68 labeled LM3 PET/CT in neuroendocrine tumors across Phase 1 and Phase 2, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Gallium-68 labeled LM3 PET/CT (Gallium-68 labeled LM3)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED